Ruth Gordillo, Ph.D.
Director, Metabolic Phenotyping Core
Dr. Gordillo was born in Badajoz, Spain. She earned her B.S. and Ph.D. degrees in Chemistry from the University of Extremadura. She came to the USA as a postdoctoral researcher at the University of California in Los Angeles in the Department of Chemistry and Biochemistry. Dr. Gordillo joined UT Southwestern in 2011 and became the director of the Metabolic Phenotyping core in 2015.
The Touchstone Diabetes Center is devoted to the study of the cells and tissues that are either contributing to or are affected by diabetes and its related diseases. Research in the Touchstone Diabetes Center focuses on both basic and clinical aspects of Type 1 and Type 2 diabetes, and questions related to the impact of diabetes and obesity on cardiovascular disease outcome, renal disease and cancer progression.
Dr. Gordillo specializes in the development of LC/MS/MS technologies for the determination and quantitation of metabolites. Our analytical portfolio includes the exploration of sphingolipids and phospholipids, water soluble cellular metabolites, diastereomeric separations of carbohydrates and nucleotide sugars, and therapeutic antibodies.
Richard (Max) Wynn, Ph.D.
Dr. Wynn received a B.S. degree in both Biology and Chemistry from McMurry University followed by advanced degrees in Chemistry and Biochemistry from Texas Tech University. His postdoctoral work in protein chemistry was in Dr. Richard Malkin’s lab at UC Berkeley. In 1989, Dr. Wynn joined the laboratory of Drs. David Chuang and Rody Cox, at UT Southwestern Medical center. He joined the Metabolic Phenotyping Core lab in November 2019.
Most of his research career has been spent working on protein purification, isolation and characterization of macromolecular complexes and protein crystallization. In 2010, he began to explore small molecule drug discovery in order to produce kinase inhibitors for the mitochondrial BCKDC kinase (BDK) and the pyruvate dehydrogenase kinases (PDKs isoforms 1-4). He has used structure-based design to develop a new generation of small-molecule inhibitors specific to BDK and pan-PDK’s. These kinase inhibitors have shown good promise in promoting oxidation of glucose and of branched-chain amino acids, while reducing lipogenesis in animal models for obesity and type 2 diabetes.
Dr. Wynn is currently responsible for operations, consulting and training on the SeaHorse XFe24 Flux analyzer for both cell culture or whole tissue samples, FPLC protein and lipoprotein fractionation/analysis, the VITROS metabolite clinical analyzer, Milliplex (MagPix) cytokine/chemokine multiplex plate assays, consulting with researchers on desired assays and data analysis, personnel training for bomb calorimetry and multiple plate assays. Dr. Wynn has extensive mouse experience and is capable of providing users and personnel training across multiple levels of experimentation.
Syann Lee, Ph.D.
Co-Director, Metabolic Phenotyping Core
B.S. in Biology from Texas Woman’s University